All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for youFind out more
Bookmark this article
On January 5, 2023, JBI-802, an oral, potent, selective dual inhibitor of two epigenetic targets of the transcriptional regulator CoREST complex, LSD1 and HDAC6, was granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of patients with acute myeloid leukemia.1
This designation is based on several relevant preclinical models, including erythroid leukemia, where JBI-802 demonstrated synergistic antitumor activity and a favorable safety profile.1
JBI-802 also received orphan drug designation for the treatment of small cell lung cancer.1 The first-in-human trial evaluating JBI-802 in multiple neuroendocrine tumors is ongoing, with plans to expand into hematologic cancers, including acute myeloid leukemia, essential thrombocythemia, and other myeloproliferative cancers.1
What time is the right time for transplantation?
On June 29, 2023, the AML Hub hosted a discussion on “What time is the right time for transplantation?”, chaired by Selina Luger, with contributions from Gert Ossenkoppele, Jeffrey Lancet, Yasushi...
The NOPHO-DB-SHIP consortium recommendations for supportive care in pediatric AML
A summary of recommendations published in Expert Review of Anticancer Therapy by Arad-Cohen, et al. They include general management of children and adolescent patients...
Subscribe to get the best content related to AML delivered to your inbox